Date: 2014-02-06
Type of information: Private placement
Company: Mologen (Germany)
Investors:
Amount: €15.7 million
Funding type: private placement
Planned used: The proceeds from the capital increase will be used to further strengthen the equity base as well as to finance the development of the product pipeline and the proceeds enable in particular to start the planned pivotal clinical phase III study with MGN1703 in metastatic colorectal cancer. Mologen has also applied for a randomized, controlled clinical study to evaluate the efficacy of MGN1703 in lung cancer, which is scheduled to begin in the first half of 2014.
Others:
Therapeutic area: Cancer - Oncology